Markets

NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10

Oct 15, 2026 · 08:34 AM ET· updated 1h ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the

Why It Matters

The FDA asked NRx to change how they describe their ketamine medicine. When regulators ask for label changes, watch to see if the company can fix it quickly or if bigger problems hide underneath.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NRXP2.62

+0.03 (+1.16%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.